HealthInvest Partners AB Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

HealthInvest Partners AB purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 98,974 shares of the biopharmaceutical company's stock, valued at approximately $8,018,000. Gilead Sciences accounts for approximately 6.3% of HealthInvest Partners AB's investment portfolio, making the stock its 3rd biggest position.

A number of other large investors have also recently made changes to their positions in GILD. PCA Investment Advisory Services Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at about $25,000. OFI Invest Asset Management bought a new position in shares of Gilead Sciences during the third quarter valued at about $26,000. Tompkins Financial Corp lifted its position in shares of Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $29,000. Finally, Sanctuary Wealth Management L.L.C. bought a new position in shares of Gilead Sciences during the fourth quarter valued at about $33,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.44 during mid-day trading on Tuesday, hitting $67.31. 4,974,933 shares of the stock traded hands, compared to its average volume of 7,347,536. The business's 50-day moving average price is $72.61 and its 200 day moving average price is $76.78. The company has a market cap of $83.81 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19. Gilead Sciences, Inc. has a 12-month low of $67.18 and a 12-month high of $87.86. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts' consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The company had revenue of $7.12 billion during the quarter, compared to analysts' expectations of $7.10 billion. During the same period in the prior year, the firm earned $1.67 EPS. Gilead Sciences's quarterly revenue was down 3.7% on a year-over-year basis. On average, analysts expect that Gilead Sciences, Inc. will post 7.08 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.75. Gilead Sciences's dividend payout ratio (DPR) is presently 68.44%.

Analyst Upgrades and Downgrades

Several brokerages have commented on GILD. Barclays lowered their price objective on shares of Gilead Sciences from $85.00 to $80.00 and set an "equal weight" rating on the stock in a research report on Monday, February 12th. Cantor Fitzgerald lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 7th. Wells Fargo & Company lowered their price objective on shares of Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating on the stock in a research report on Monday, March 4th. StockNews.com raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, March 26th. Finally, Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $85.36.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company's stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.29% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.